An observational study of the use of beclomethasone dipropionate suppositories in the treatment of lower urinary tract inflammation in men

Abstract

BackgroundNonbacterial prostatitis, together with chronic pelvic pain syndrome, accounts for 90–95 % of prostatitis cases. Anti-inflammatory medications are commonly used to reduce storage/inflammatory symptoms that can deteriorate quality of life. The purpose of this study was to observe the efficacy and safety of beclomethasone dipropionate rectal suppositories (Topster®) in inflammations of the lower urinary tract in men.MethodsPatients underwent diagnostic and therapeutic protocols according to current evidence-based practice. Efficacy assessments: voiding parameters, perineal pain, International Prostate Symptom Score (IPSS), digital rectal examination (DRE). Adverse events and patient compliance were recorded throughout the study.ResultsOne hundred eighty patients were enrolled, mean age 52 ± 14.97. Most frequent diagnosis: nonbacterial prostatitis (85 %). All patients completed visits 1 and 2. All patients were treated with beclomethasone dipropionate (BDP) suppositories, 136/180 also with Serenoa repens (SR) extract. Antibiotics were rarely required.162/180 patients presented clinically significant improvements and terminated treatment.Mean change vs. baseline in voiding frequency: −3.55 ± 2.70 n/day in patients taking only BDP and −3.68 ± 2.81 n/day in those taking both BDP and SR (P<.0001 in both groups). Uroflowmetry improved significantly; change from baseline 3.26 ± 5.35 ml/s in BDP only group and 5.61 ± 7.32 ml/s in BDP + SR group (P = 0.0002 for BDP, P<.0001 for BDP + SR). Urine stream normal in 35 % of patients at visit 1 and 57.22 % of patients at visit 2. Mean change in perineal pain, on 0–10 VAS, −0.66 ± 2.24 for BDP only group (P = 0.0699) and −1.37 ± 2.40 for BDP + SR group (P<.0001). IPSS increased at visit 2. No adverse events were reported.For all parameters, none of the comparisons between groups was found to be statistically significant.ConclusionThis study confirmed the drug’s good safety profile. We also observed an improvement in the main storage symptoms and clinical findings associated with lower urinary tract inflammation in patients treated with beclomethasone dipropionate suppositories.

A phase II, randomized, single-blinded, placebo-controlled clinical trial on the efficacy of Curcumina and Calendula suppositories for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome type III

“…In addition, numerous lines of evidence have indicated Curcuma longa (turmeric) ability in modulating multiple cell signaling molecules such as pro-inflammatory cytokines (tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6), apoptotic proteins, NF-κB, cyclooxygenase (COX)-2, STAT3, IKKβ, endothelin-1, malondialdehyde (MDA). There are some evidences about rectal therapies with corticosteroids in patients with CP/CPSS, showing better drug' s good safety profile and improving main storage symptoms and clinical findings associated with lower urinary tract inflammation in patients treated with beclomethasone di-propionate suppositories (9).…”

Effect on prostatic specific antigen by a short time treatment with a Curcuma extract: A real life experience and implications for prostate biopsy

“…Results showed an effect on symptoms related to prostatitis, but not on PSA levels. Authors declared that, as expected, PSA levels remained stable since it is not a specific parameter for lower urinary tract inflammation (13). But, we know from the literature that inflammation of the prostate is an histological finding in almost every set of prostate biopsies, even when there are no signs of clinical prostatitis.…”

Recent advances in managing chronic prostatitis/chronic pelvic pain syndrome

“…Newer second-generation formulations aimed at decreasing systemic activity while maintaining local efficacy such as beclomethasone dipropionate have also gained increasing interest. Bozzini et al followed 180 men with CP/CPPS who received beclomethasone dipropionate suppositories and 136 of the 180 men who also received Serenoa repens extract 30 . The authors noted that men in the steroid group versus steroid and Serenoa repens combined group had significant decreases in voiding frequency compared to baseline (–3.55 versus –3.68 voids per day, respectively) and increase in uroflowmetry (3.26 versus 5.61 mL/s, respectively).…”